News & Updates

In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.

Psoriasis patients, especially those with concomitant psoriatic arthritis (PsA), suffer from worse joint pain, leading to higher analgesic use rates than the general population, a recent study has found.

Difamilast ointment is superior to vehicle and can be a safe and effective option for the treatment of atopic dermatitis, a recent study reports.

In the phase II/III RELATIVITY-047 trial evaluating dual checkpoint inhibition for advanced melanoma, a new fixed-dose combination comprising the LAG-3 inhibitor relatlimab and the PD-1 inhibitor nivolumab fared better than nivolumab monotherapy.

Convolutional neural networks (CNN) can outperform less-experienced pathologists at discriminating melanomas from nevi, reports a recent study. For experienced pathologists, CNNs may still be helpful as a form of triage.

A novel transdermal device for the delivery of triamcinolone demonstrates efficacy comparable to that of conventional topical steroids in the treatment of nail psoriasis, according to a Singapore study.

A registry-based study has recently shown diverse COVID-19 vaccine-associated dermatologic reactions, including papulovesicular, pityriasis rosea-like, and papulosquamous eruptions classified as vaccine-related eruption of papules and plaques (V-REPP).